The FEBS Journal

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

Transplantation and Cellular Therapy

Trial in progress: QUINTESSENTIAL-2—a phase 3 Study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Journal of Translational Medicine

Long-term follow-up results of anti-BCMA CAR-T cell therapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory multiple myeloma with extramedullary disease

The Asco Post

Off-the-shelf CAR T-cell therapy produces deep, durable responses in heavily pretreated multiple myeloma

Cancer Medicine

Lenalidomide plus dexamethasone as first-line therapy in transplant-ineligible patients with multiple myeloma

BMC Infectious Diseases

Machine learning triumphs in differentiating fungal and bacterial infections

Blood Advances

BCMA/CD19 dual-targeting CAR T cell therapy in older patients with newly diagnosed multiple myeloma: A phase I study

American Journal of Hematology

The role of bispecific antibodies in relapsed/refractory multiple myeloma with renal impairment: A systematic review

Cancer Control

The changing landscape of second primary malignancies in multiple myeloma: A SEER population-based study between two therapeutic eras

Frontiers in Digital Health

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic